Abdominal pain. (1995) comparing pantoprazole to omeprazole for the treatment of acute duodenal ulcer in 270 patients suggested that the agents were equally effective in the promotion of ulcer healing and management of ulcer-related pain at 2 and 4 weeks. There were no clinically-relevant differences between pantoprazole and omeprazole in the rate of duodenal ulcer healing, nor were there clinically-relevant differences in ulcer-related pain reduction in response to treatment after 2 weeks. Pantoprazole and omeprazole differ in: official U.S. FDA-authorized medical indications; bioavailability; developers, date of development, and release date; formatting options; and legal status (U.S.). Among the intent-to-treat participants, 4-week and 8-week healing rates were: 75% and 90% among users of 40 mg/day pantoprazole versus 70% and 86.6% among users of 20 mg/day omeprazole. Though all PPIs function by blocking the final step in stomach acid production, they do have some important differences. Results indicated that 24-hour intragastric pH among patients with Zollinger-Ellison syndrome did not differ among treatments (omeprazole, lansoprazole, and pantoprazole). It was concluded that pantoprazole appears to be equally effective to omeprazole for the treatment of duodenal ulcer. Relapse occurs frequently after treatment withdrawal. Edited by three highly acclaimed academic anesthetic pharmacologists, with contributions from an international team of experts, and illustrated in full colour, this is a sophisticated, user-friendly resource for all practitioners providing ... Prilosec (omeprazole) Nexium (esomeprazole) Prevacid (lansoprazole) Pepcid (famotidine) Tagamet (cimetidine) People who want to switch medications should speak with their medical providers before stopping any medications. Omeprazole and esomeprazole therapy are both associated with a low rate of transient and asymptomatic serum aminotransferase elevations and are rare causes of clinically apparent liver injury. 2000: Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil. tell your doctor and pharmacist if you are allergic to omeprazole, dexlansoprazole (Dexilant), esomeprazole (Nexium), lansoprazole (Prevacid, in Prevpac), pantoprazole (Protonix), rabeprazole (Aciphex), any other medications, or any of the ingredients in the omeprazole product you will be taking. Headache. Although it is well-established that pantoprazole and omeprazole are efficacious in the treatment of erosive esophagitis (a condition associated with GERD), of these agents, only omeprazole is officially approved by the FDA as a direct treatment for GERD. Although esomeprazole (40 mg/day) facilitated faster symptom relief than other proton-pump inhibitors, healing rates of erosive reflux esophagitis in esomeprazole users did not significantly differ from users of other proton-pump inhibitors – as evidenced by high-resolution patient endoscopy. (2017) ranked pantoprazole (40 mg/day) as the top intervention for duodenal ulcers over a 4-week period (based on its highest probability of having the best ulcer healing rate). When pantoprazole was co-administered with 2 antibiotics as part of a “triple therapy,” 7-day cure rates were: 84% (pantoprazole with clarithromycin and nitroimidazole), 78% (pantoprazole with amoxicillin and clarithromycin), and 74% (pantoprazole with amoxicillin and nitroimidazole) – supporting the idea that pantoprazole helps eradicate H. Pylori with antibiotics. Stay fully up to date in this fast-changing field with Infectious Disease and Pharmacology, an all-new volume in the series. This review and meta-analysis provides strong data to support the use of pantoprazole (in conjunction with antibiotics) in the treatment of H. Pylori infection – and indicates that its efficacy does not differ from omeprazole (an FDA-approved agent) for this condition. Pantoprazole and Omeprazole are medications classified as proton-pump inhibitors (PPIs) and are commonly prescribed for the management of medical conditions in which stomach acid reduction is of therapeutic benefit. The information on ConsumerSafety.org is provided for informational purposes only and is not intended to provide specific legal advice. For this reason, most experts believe that flexibly-dosed pantoprazole is as effective as flexibly-dosed omeprazole in the treatment of gastroesophageal reflux disease (GERD), duodenal ulcer, gastric ulcer, and H. Pylori infection. All of the studies, except for two that compared esomeprazole and omeprazole, found that there were no differences among the PPIs in the treatment of GERD. Caro et al. There … There has been evidence of PPI cross-sensitivity in some sensitive individuals in literature reports. For this reason, it cannot be suggested that one agent (pantoprazole or omeprazole) exhibits greater efficacy than the other in treating stomach acid hypersecretory conditions. You should not use Nexium if you are allergic to esomeprazole or to similar medicines such as lansoprazole , omeprazole (Prilosec, Zegerid), pantoprazole , or rabeprazole . URL of this page: https://medlineplus.gov/druginfo/meds/a693050.html. esomeprazole; lansoprazole; measles, mumps, rubella, and varicella vaccine, live; nizatidine; omeprazole; pantoprazole; rabeprazole; ranitidine; varicella virus vaccine live; Mesalamine has moderate interactions with at least 48 different drugs. Meneghelli et al. Oncotarget, 8(41), 70332. Authors of the meta-analysis concluded that pantoprazole (40 mg/day) appears safe and effective for alleviating symptoms of gastroesophageal reflux disease (GERD). Results of the meta-analysis indicated that the average rate of H. Pylori eradication among users of pantoprazole plus clarithromycin for 14 days was 60%. You should not use Nexium if you are allergic to esomeprazole or to similar medicines such as lansoprazole , omeprazole (Prilosec, Zegerid), pantoprazole , or rabeprazole . Unless your doctor tells you otherwise, continue your normal diet. Beker et al. A similar reduction in antiplatelet activity was observed with esomeprazole when given concomitantly with Plavix. Learn how your comment data is processed. For the study, a total of 669 outpatients diagnosed with moderate-to-severe gastroesophageal reflux disease (verified by endoscopy) were assigned at random to receive either: pantoprazole (40 mg/day) or omeprazole MUPS (40 mg/day). © MentalHealthDaily.com 2013-2019 | Privacy Policy | Legal Notice | Affiliate Disclosure, https://www.ncbi.nlm.nih.gov/pubmed/28953640, https://www.ncbi.nlm.nih.gov/pubmed/19248200, https://www.ncbi.nlm.nih.gov/pubmed/12743434, https://www.gastrojournal.org/article/S0016-5085(00)82138-1/pdf, https://www.ncbi.nlm.nih.gov/pubmed/10705625, https://www.ncbi.nlm.nih.gov/pubmed/12755837, https://www.ncbi.nlm.nih.gov/pubmed/12070410, https://www.ncbi.nlm.nih.gov/pubmed/16423003, https://www.ncbi.nlm.nih.gov/pubmed/2007355, https://www.ncbi.nlm.nih.gov/pubmed/29657605, https://www.ncbi.nlm.nih.gov/pubmed/24347282, https://www.ncbi.nlm.nih.gov/pubmed/25510089, https://www.ncbi.nlm.nih.gov/pubmed/18360632, https://www.ncbi.nlm.nih.gov/pubmed/18044079, https://www.ncbi.nlm.nih.gov/pubmed/24672134, https://www.ncbi.nlm.nih.gov/pubmed/15709887, https://www.ncbi.nlm.nih.gov/pubmed/11519776/, https://www.ncbi.nlm.nih.gov/pubmed/11110229, https://www.ncbi.nlm.nih.gov/pubmed/10430350, https://www.ncbi.nlm.nih.gov/pubmed/28139495, https://www.ncbi.nlm.nih.gov/pubmed/12119060, https://www.ncbi.nlm.nih.gov/pubmed/10638560, https://www.ncbi.nlm.nih.gov/pubmed/10975769, https://www.ncbi.nlm.nih.gov/pubmed/7614102, https://www.ncbi.nlm.nih.gov/pubmed/8527617, https://www.ncbi.nlm.nih.gov/pubmed/8180296, https://www.ncbi.nlm.nih.gov/pubmed/8180295, https://www.ncbi.nlm.nih.gov/pubmed/1471382, https://www.ncbi.nlm.nih.gov/pubmed/15095858, https://www.ncbi.nlm.nih.gov/pubmed/9872516, https://pubchem.ncbi.nlm.nih.gov/compound/pantoprazole, https://pubchem.ncbi.nlm.nih.gov/compound/omeprazole, https://www.ncbi.nlm.nih.gov/pubmed/8738854, https://www.ncbi.nlm.nih.gov/pubmed/15258107, https://www.ncbi.nlm.nih.gov/pubmed/8930576, https://www.researchgate.net/publication/286716167, https://www.ncbi.nlm.nih.gov/pubmed/11117653, https://www.ncbi.nlm.nih.gov/pubmed/28102361, Lexapro (Escitalopram) vs. Prozac (Fluoxetine), Lexapro (Escitalopram) vs Zoloft (Sertraline): Extensive Comparison. Talk to your doctor or pharmacist about how these acid reflux drugs could affect you. This means that it’ll take between 4.95 and 10.45 hours to eliminate pantoprazole from systemic circulation and between 2.75 and 11 hours to eliminate omeprazole from systemic circulation – following cessation. Attorney Advertising. Both pantoprazole and omeprazole are indicated by the U.S. FDA as (1) maintenance therapies to promote healing of erosive esophagitis and as (2) interventions for stomach acid hypersecretory conditions like Zollinger-Ellison syndrome. 14. Patients can find warnings about acute interstitial nephritis on the drug labels for each of these proton pump inhibitors. Store it at room temperature and away from light, excess heat, and moisture (not in the bathroom). The elimination half-life range estimated for pantoprazole (0.9 to 1.9 hours) is slightly narrower than the elimination half-life range estimated for omeprazole (0.5 to 2 hours). Zollinger-Ellison syndrome). In other words, because H+/K+-ATPase enzymes act as acid pumps within the gastric mucosa (mucous membrane layer of the stomach), their inhibition [by pantoprazole or omeprazole] interferes with the final step of endogenous stomach acid production. A complete health manual that examines each system of the aging baby-boomer's body, discussing how to prevent problems, ways to avert them, and what to do if they are already full blown Additional withdrawal symptoms resulting from cessation of proton-pump inhibitors [as reported by former users] include: appetite changes; stomach aches; constipation or diarrhea; nausea and/or vomiting; and neuropsychiatric symptoms (e.g. It should be noted that both delayed-release pantoprazole pills and injectable pantoprazole solution contain “pantoprazole sodium,” however, preparations of pantoprazole containing “pantoprazole magnesium” are available in countries outside the United States. You may have a more serious condition that cannot be treated with nonprescription medication. In this study by Janssen et al., 558 individuals with endoscopy-confirmed, mild GERD were assigned to receive pantoprazole (20 mg) “on-demand” or “continuously” over a 24-week period. If your condition does not improve or gets worse, call your doctor. Furthermore, it seems as though pantoprazole and omeprazole may differ slightly in metabolism and elimination half-life. you are allergic to esomeprazole or to similar medicines such as lansoprazole, omeprazole, pantoprazole, rabeprazole, Dexilant, Nexium, Prevacid, Protonix, and others. “healing rate”) at 4 weeks of treatment. Results of the study indicated that pantoprazole significantly alleviated GERD-related symptoms in ~82.1% of per-protocol patients and in ~79.1% of intent-to-treat patients – over an acute period (4 weeks). All of the studies, except for two that compared esomeprazole and omeprazole, found that there were no differences among the PPIs in the treatment of GERD. If you are using the 10-mg packet, place 1 tablespoonful (15 mL) of water in a container. Take this medication by mouth as … If you are taking the delayed-release tablets, swallow them whole with a full glass of water. Currently, pantoprazole and omeprazole have 2 mutual FDA-authorized indications: (1) promoting healing in erosive esophagitis and (2) treating stomach acid hypersecretory conditions (e.g. Moreover, brand name Prilosec OTC (20 mg) costs ~$24 for a 42-pill supply – making Prilosec OTC significantly less expensive than standard brand name Protonix and Prilosec prescriptions. pyridine and/or benzimidazole rings), their pharmacological profiles are extremely similar. Whilst most pharmacy undergraduate texts are subject specific, "Pharmacy Case Studies" encourages students to take an integral approach to pharmacy via a series of pharmacy cases. Information is also available online at https://www.poisonhelp.org/help. sought to compare the efficacies of pantoprazole and omeprazole in the treatment of acute duodenal ulcer – and conducted a randomized, double-blind, multicenter trial. It is also important information to carry with you in case of emergencies. LiverTox. This study supports the idea that pantoprazole (40 mg/day) and omeprazole (20 mg/day) do not significantly differ in efficacy for the promotion of healing in erosive esophagitis. Below is a review and meta-analysis in which the effectiveness of pantoprazole in H. Pylori infection was assessed. It was concluded that pantoprazole appears as potent and effective as omeprazole (and other proton-pump inhibitors) in patients with Zollinger-Ellison syndrome. That said, the aforementioned meta-analysis indicated that pantoprazole (40 mg/day) was associated with the highest cumulative probability of acceptability (85.2%) and omeprazole (20 mg/day) was associated with the second-highest cumulative probability of acceptability (74.3%) of the 8 interventions (7 proton-pump inhibitors, 1 placebo). Zheng conducted a study in which the efficacies of various proton-pump inhibitors including omeprazole and pantoprazole were compared in the treatment of reflux esophagitis. The U.S. Food and Drug Administration (FDA) approved the first prescription proton-pump inhibitor (PPI) in 1989 as a treatment for heartburn caused by acid reflux. A total of 552 patients (of 669) completed the study: 282 pantoprazole users (40 mg/day) and 270 omeprazole MUPS users (40 mg/day) – and of study completers, 452 patients (of 552) were “highly-compliant” (233 pantoprazole users and 219 omeprazole users). Used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions involving excessive stomach acid is used to treat certain conditions where there is … Read more. However, if controlling for differences in potency of dose (such as by administering equipotent doses), most gastroenterologists and medical doctors believe that pantoprazole and omeprazole are equally effective – regardless of the medical condition for which they’re administered. Keep all appointments with your doctor and the laboratory. Reflecting upon the official FDA-authorized uses for pantoprazole and omeprazole, it seems as though both medications are approved as: (1) maintenance therapies to promote healing in erosive esophagitis and (2) as treatments for stomach acid hypersecretory conditions like Zollinger-Ellison syndrome. It was concluded that pantoprazole (intravenous or oral) leads to fast resolution of GERD symptoms and high healing rates. To use the sharing features on this page, please enable JavaScript. pairing with sodium bicarbonate vs. magnesium). Specifically, after a 4-week treatment period, 65.3% of pantoprazole users and 66.3% of omeprazole users exhibited healing. In the standalone small-scale study by Ramdani et al. If attempting to decide whether pantoprazole or omeprazole might be “better” (on average) than the other – it’s necessary to compare these medications in domains that prospective users and/or medical professionals would care most about, including: (1) efficacy (in specific medical conditions) and (2) tolerability. Although the lowest reflux esophagitis relapse rate was observed among users of 40 mg/day pantoprazole (17%), this was not significantly different from the reflux esophagitis relapse rates associated with 20 mg/day pantoprazole (23%) or 20 mg/day omeprazole (19%), respectively. Among adults who received high-dose methotrexate (median dose of 3500 mg/m2, range of 1000-5000 mg/m2), coadministration of PPIs such as omeprazole, lansoprazole, or rabeprazole was identified as a risk factor for delayed methotrexate elimination with an OR of 2.65 (95% confidence interval 1.036.82). In this review, efficacies of proton-pump inhibitors were determined by healing and relapse rates of GERD following treatment. Any patient with a known PPI allergy should not take that drug. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. Esomeprazole and rabeprazole are CYP2C19-independent PPIs, whereas lansoprazole and omeprazole are CYP2C19 dependent. Instead, the best way to dispose of your medication is through a medicine take-back program. Though researchers cannot agree on the biological rationale for it, PPIs seem to increase the risk of a very serious kind of diarrhea associated with Clostridium difficile (C. dif) bacteria.